Sanofi India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India reported Q1 FY26 revenue from operations of ₹4,063 million, down 12.3% from ₹4,635 million in the same quarter last year. Profit after tax (continuing operations) for the quarter was ₹695 million, slightly up from ₹682 million, translating to basic EPS of ₹30.18 versus ₹29.62. For the half-year ended June 30, 2025, revenue from continuing operations fell 3.3% to ₹9,422 million, while profit from continuing operations rose to ₹1,890 million from ₹1,402 million. The company disclosed a new promotion and distribution agreement with Emcure Pharmaceuticals for its Oral Anti-diabetic (OAD) business. The Board also noted the retirement of Whole-time Director Ms. Renee Amonkar and the appointment of Mr. Mahadev Gawade in her place, effective August 11, 2025.
The double-digit quarterly revenue decline is a notable concern, though PAT held steady, suggesting cost discipline. Investors should watch the new Emcure OAD partnership for future revenue traction, while director transition at the Goa site is a routine succession.